ProQR Therapeutics N.V. (PRQR)


+0.03 (+3.70%)
Symbol PRQR
Price $0.8278
Beta 0.805
Volume Avg. 0.41M
Market Cap 59.074M
Shares () -
52 Week Range 0.53-8.67
1y Target Est -
DCF Unlevered PRQR DCF ->
DCF Levered PRQR LDCF ->
ROE -58.14% Strong Sell
ROA -34.96% Strong Sell
Operating Margin -
Debt / Equity 105.39% Buy
P/E -
P/B 0.57 Buy


Consensus EPS

Upgrades & Downgrades

Latest PRQR news

Mr. Daniel De Boer
NASDAQ Global Market

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.